Business Context and Reporting Period
This Form 8-K Current Report was filed by Organogenesis Holdings Inc. on May 3, 2022, with the earliest event reported on the same date. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance.
Material Changes
The material change reported is the appointment of two new independent directors to the Board of Directors, effective May 3, 2022:
- Michele I. Korfin
- Gilberto Quintero
With these appointments, the Board now consists of eleven members, six of whom are independent, satisfying the majority independence requirement under Nasdaq listing standards.
Compensation and Governance Details
The filing outlines the compensatory arrangements for the new directors:
- Annual Retainer: $55,000 per director.
- Equity Award: 23,913 restricted stock units (RSUs) per director, vesting on May 3, 2023.
- Agreements: Both directors received standard indemnification and change in control retention agreements.
Investor Verification Checklist
- Verify the independence status of the new directors against Nasdaq listing standards.
- Confirm the vesting schedule and potential dilution impact of the 47,826 total RSUs awarded.
- Review the attached press release (Exhibit 99.1) for additional biographical details on the new appointees.